UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
Effective August 23, 2021, Mednax, Inc., a Florida corporation (the “Company”), reduced the revolving commitments under the Company’s Credit Agreement, dated as of October 30, 2017 (as amended through the date hereof, the “Credit Agreement”), by and among the Company, certain of its domestic subsidiaries and affiliated professional contractors from time to time party thereto as guarantors, the lenders parties thereto and JPMorgan Chase Bank, N.A. as administrative agent for the lenders, from $1.2 billion to $600.0 million. At August 23, 2021, the Company had no outstanding principal balance on the Credit Agreement and had one outstanding letter of credit of $0.1 million, which reduced the amount available on the Credit Agreement to $299.9 million at August 23, 2021, after giving effect to the revolving commitment reduction and the temporary requirement that the Company maintain minimum availability under the Credit Agreement of $300.0 million through the third quarter of 2021.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Mednax, Inc. |
|
|
|
|
Date: |
August 27, 2021 |
By: |
/s/ C. Marc Richards |
|
|
|
C. Marc Richards |